Prevalence of CEA, CA 125, and CA 15-3 serum tumour markers in different regions of Saudi Arabia

References

1. 1.↵
   1. Bray F,
   2. Laversanne M,
   3. Weiderpass E,
   4. Soerjomataram I

   . The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 2021; 127: 3029–3030.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Duffy MJ

   . Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 2001; 38: 225–262.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Filella X,
   2. Rodríguez-Garcia M,
   3. Fernández-Galán E

   . Clinical usefulness of circulating tumor markers. Clin Chem Lab Med 2022; 61: 895–905.

   OpenUrl
4. 4.
   1. Molina R,
   2. Marrades RM,
   3. Augé JM,
   4. Escudero JM,
   5. Viñolas N,
   6. Reguart N, et al.

   Assessment of a combined panel of 6 serum tumor markers for lung cancer. Am J Respir Crit Care Med 2016; 193: 427–437.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Mazzone PJ,
   2. Wang XF,
   3. Han X,
   4. Choi H,
   5. Seeley M,
   6. Scherer R, et al.

   Evaluation of a serum lung cancer biomarker panel. Biomark Insights 2018; 13: 1177271917751608.

   OpenUrl
6. 6.
   1. Doseeva V,
   2. Colpitts T,
   3. Gao G,
   4. Woodcock J,
   5. Knezevic V

   . Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer. J Transl Med 2015; 13: 55.

   OpenUrl
7. 7.↵
   1. Cohen JD,
   2. Li L,
   3. Wang Y,
   4. Thoburn C,
   5. Afsari B,
   6. Danilova L, et al.

   Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018; 359: 926–930.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Jacobs I,
   2. Bast RC Jr.

   . The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4: 1–12.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Sturgeon CM,
   2. Duffy MJ,
   3. Walker G

   . The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory. Ann Clin Biochem 2011; 48: 295–299.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Berry N,
    2. Jones DB,
    3. Smallwood J,
    4. Taylor I,
    5. Kirkham N,
    6. Taylor-Papadimitriou J

    . The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer. Br J Cancer 1985; 51: 179–186.

    OpenUrlPubMed
11. 11.↵
    1. Gold P,
    2. Freedman SO

    . Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439–462.

    OpenUrlAbstract
12. 12.↵
    1. Konishi T,
    2. Shimada Y,
    3. Hsu M,
    4. Tufts L,
    5. Jimenez-Rodriguez R,
    6. Cercek A, et al.

    Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol 2018; 4: 309–315.

    OpenUrl
13. 13.↵
    1. Mukama T,
    2. Fortner RT,
    3. Katzke V,
    4. Hynes LC,
    5. Petrera A,
    6. Hauck SM, et al.

    Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer. Br J Cancer 2022; 126: 1301–1309.

    OpenUrlCrossRef
14. 14.↵
    1. Lertkhachonsuk AA,
    2. Buranawongtrakoon S,
    3. Lekskul N,
    4. Rermluk N,
    5. Wee-Stekly WW,
    6. Charakorn C

    . Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors. J Obstet Gynaecol Res 2020; 46: 2287–2291.

    OpenUrlCrossRef
15. 15.↵
    1. Gao Y,
    2. Wang J,
    3. Zhou Y,
    4. Sheng S,
    5. Qian SY,
    6. Huo X

    . Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer. Sci Rep 2018; 8: 2732.

    OpenUrl
16. 16.↵
    1. Nah EH,
    2. Cho S,
    3. Park H,
    4. Kim S,
    5. Kwon E,
    6. Cho HI

    . Establishment and validation of reference intervals for tumor markers (AFP, CEA, CA19-9, CA15-3, CA125, PSA, HE4, Cyfra 21-1, and ProGRP) in primary care centers in Korea: a cross-sectional retrospective study. Health Sci Rep 2023; 6: e1107.

    OpenUrl
17. 17.↵
    1. Yang Q,
    2. Zhang P,
    3. Wu R,
    4. Lu K,
    5. Zhou H

    . Identifying the best marker combination in CEA, CA125, CY211, NSE, and SCC for lung cancer screening by combining ROC curve and logistic regression analyses: is it feasible? Dis Markers 2018; 2018: 2082840.

    OpenUrl
18. 18.↵
    1. Sekiguchi M,
    2. Matsuda T

    . Limited usefulness of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for gastrointestinal and whole-body cancer screening. Sci Rep 2020; 10: 18202.

    OpenUrl
19. 19.↵
    1. Feng F,
    2. Tian Y,
    3. Xu G,
    4. Liu Z,
    5. Liu S,
    6. Zheng G, et al.

    Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. BMC Cancer 2017; 17: 737.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Nam SE,
    2. Lim W,
    3. Jeong J,
    4. Lee S,
    5. Choi J,
    6. Park H, et al.

    The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry. Breast Cancer Res Treat 2019; 177: 669–678.

    OpenUrl